论文部分内容阅读
目的 观察低分子肝素对Ⅱ型糖尿病肾病的保护及治疗作用 .方法 选用 36例Ⅱ型糖尿病肾病患者 ,按尿蛋白定性分蛋白阴性而尿微量白蛋白排泄率 (UAER)≥ 2 0 μg/min的微量白蛋白尿组 (A组 ) 2 1例和尿蛋白阳性的蛋白尿组 (B组 ) 15例 ,给予低分子肝素肌注 ,5次 /周 ,疗程 3周 .观察低分子肝素对Ⅱ型糖尿病肾病患者尿微量白蛋白排泄率 (UAER)和尿蛋白的影响 .结果 与治疗前比较 ,治疗后A组和B组的UAER降低分别为(44 .5± 16 .2 ) %和 (5 0 .1± 2 1.4 ) % ,(P <0 .0 5 ) ,但两组比较无显著差异 (P <0 .0 5 ) .B组能降低尿蛋白 ,且下降率为 (6 7.6± 2 1.4 ) % ,(P <0 .0 5 ) .疗程中未见严重的不良反应 .结论 低分子肝素通过降低尿微量白蛋白排泄率 (UAER) ,尿蛋白对Ⅱ型糖尿病肾病起到保护和治疗作用
Objective To observe the protective and therapeutic effects of low molecular weight heparin on type Ⅱ diabetic nephropathy.Methods 36 patients with type Ⅱ diabetic nephropathy were divided into two groups according to urinary protein qualitative protein negative and urinary albumin excretion rate (UAER) ≥ 20 μg / min 15 cases of microalbuminuria (group A) and 15 cases of proteinuria (group B) were given intramuscular injection of LMWH for 5 times / week for 3 weeks.The effects of low molecular weight heparin on type Ⅱ Urinary albumin excretion rate (UAER) and urinary protein in patients with diabetic nephropathy.Results Compared with those before treatment, the UAER decreased in group A and group B after treatment were (44.5 ± 16.2)% and (50 .1 ± 2 1.4%, P <0.05), but there was no significant difference between the two groups (P <0.05) .B group can reduce urine protein, and the rate of decrease was (6 7.6 ± 2 1.4 ) (P <0.05) .There was no serious adverse reaction during the course of treatment.Conclusion Low-molecular-weight heparin can protect and treat type 2 diabetic nephropathy by decreasing the urinary microalbumin excretion rate (UAER)